As­traZeneca and Am­gen qui­et­ly ad­mit teze­pelum­ab set­back as the Dupix­ent chal­lenger heads to FDA

As­traZeneca and Am­gen have block­buster am­bi­tions for their teze­pelum­ab an­ti­body, aim­ing to chal­lenge the Re­gen­eron and Sanofi gi­ant Dupix­ent in asth­ma and re­lat­ed res­pi­ra­to­ry mal­adies. But as part of its sec­ond quar­ter up­date Thurs­day morn­ing, the big British drug­mak­er qui­et­ly scut­tled plans in an­oth­er in­di­ca­tion, rais­ing doubt over how big a bite it will take out of the Dupix­ent pie.

Af­ter flunk­ing two Phase II stud­ies in atopic der­mati­tis, As­traZeneca dropped plans for teze­pelum­ab to treat the con­di­tion al­to­geth­er, the com­pa­ny re­vealed Thurs­day morn­ing. The move comes just a few weeks af­ter the an­ti­body won pri­or­i­ty re­view from the FDA in asth­ma, where a de­ci­sion is ex­pect­ed in the first quar­ter next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.